Moderna, Inc. (MRNA) Shares Outstanding: 0.39
Is Moderna, Inc.’s shares outstanding high or low?
Moderna, Inc.'s shares outstanding of 0.39 is in line with its 5-year average of 0.39, around the middle of its 5-year range (0.38–0.40).
The shares outstanding for Moderna, Inc. (MRNA) is 0.39. It is above its 12-month average by 0.65% (0.39).
MRNA Shares Outstanding Chart
MRNA Average Shares Outstanding Chart
MRNA Current vs Average Shares Outstanding Chart
MRNA Shares Outstanding Metrics
SHARES OUTSTANDING
0.39
SHARES OUTSTANDING AVG TTM
0.39
SHARES OUTSTANDING AVG 3Y
0.39
SHARES OUTSTANDING AVG 5Y
0.39
SHARES OUTSTANDING AVG 10Y
0.34
SHARES OUTSTANDING AVG 15Y
0.34
SHARES OUTSTANDING AVG 20Y
0.34
CURRENT VS TTM AVG
+0.65%
CURRENT VS 3Y AVG
+0.45%
CURRENT VS 5Y AVG
+0.03%
CURRENT VS 10Y AVG
+13.31%
CURRENT VS 15Y AVG
+13.31%
CURRENT VS 20Y AVG
+13.31%
Share Structure
Shares Outstanding
389.00M
Float Shares
N/A
Stock Price
$46.48
Market Cap
$18.4B
Annual Shares Outstanding History
| Year | Weighted Average Shares | YoY Change |
|---|---|---|
| 2025 | 389.00M | +1.30% |
| 2024 | 384.00M | +0.52% |
| 2023 | 382.00M | -3.05% |
| 2022 | 394.00M | -2.23% |
| 2021 | 403.00M | +5.68% |
| 2020 | 381.33M | +15.28% |
| 2019 | 330.80M | +0.61% |
| 2018 | 328.80M | -12.55% |
| 2017 | 376.00M | +486.64% |
| 2016 | 64.09M | - |
Relationship: Market Cap = Shares Outstanding × Stock Price
Key concepts:
- Float shares: Shares available for public trading
- Dilution: When new shares are issued, existing shareholders own less
- Buybacks: Reduce share count, increasing EPS and ownership stake
- Stock splits: Increase share count but don't change market cap
Moderna, Inc. Shares Outstanding Formula & Definition
Shares Outstanding represents the total number of shares issued by a company that are held by all shareholders. Changes in share count affect EPS and ownership dilution.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Moderna, Inc. Shares Outstanding FAQ
- What is the shares outstanding for Moderna, Inc. (MRNA)?
- The shares outstanding for MRNA stock is 0.39.
- Is Moderna, Inc.'s shares outstanding high or low?
- Moderna, Inc.'s shares outstanding of 0.39 is in line with its 5-year average of 0.39, around the middle of its 5-year range (0.38–0.40).
- What is the TTM average shares outstanding for Moderna, Inc. (MRNA)?
- The TTM average shares outstanding for MRNA stock is 0.39.
- What is the 3Y average shares outstanding for Moderna, Inc. (MRNA)?
- The 3Y average shares outstanding for MRNA stock is 0.39.
- What is the 5Y average shares outstanding for Moderna, Inc. (MRNA)?
- The 5Y average shares outstanding for MRNA stock is 0.39.
- What is the 10Y average shares outstanding for Moderna, Inc. (MRNA)?
- The 10Y average shares outstanding for MRNA stock is 0.34.
- What is the 15Y average shares outstanding for Moderna, Inc. (MRNA)?
- The 15Y average shares outstanding for MRNA stock is 0.34.
- What is the 20Y average shares outstanding for Moderna, Inc. (MRNA)?
- The 20Y average shares outstanding for MRNA stock is 0.34.
Moderna, Inc. Shares Outstanding History
| DATE | SHARES OUTSTANDING |
|---|---|
| 2025-12-31 | 0.39 |
| 2024-12-31 | 0.38 |
| 2023-12-31 | 0.38 |
| 2022-12-31 | 0.39 |
| 2021-12-31 | 0.40 |
| 2020-12-31 | 0.38 |
| 2019-12-31 | 0.33 |
| 2018-12-31 | 0.33 |
| 2017-12-31 | 0.38 |
| 2016-12-31 | 0.06 |
Related Metrics
About Moderna, Inc.
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stéphane Bancel